Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in ...

SS is a leukemic form of cutaneous T-cell lymphoma, presenting with erythroderma ... and aggressive clinical course, with median survival around 32 months. Though morphologically similar to ...

T-cell lymphomas include a number of subtypes of T cell-derived non-Hodgkins's lymphoma, including cutaneous T-cell lymphoma ... for tumor expansion and survival, representing a new and promising ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Interim Results from FDA-Funded Study Reinforces HyBryte's Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...